Navigation Links
Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics
Date:12/18/2013

DUBLIN, Dec. 18, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/mqs7t3/merger_and) has announced the addition of the "Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

The Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all merger and acquisition deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Key Topics Covered:

Executive Summary

1. Introduction

2. Trends in M&A dealmaking
2.1. Introduction
2.2. Difference between merger and acquisition deals
2.3. Trends in M&A deals since 2009
2.4. When M&A can be useful
2.5. Attributes of M&A deals
2.6. Partnering deals with M&A component
2.7. Bigpharma mega mergers - are we at the end of the road?
2.8. Accessing innovation through M&A
2.9. The emerging role of private equity in M&A
2.10. Implementing M&A transactions
2.11. Joint ventures as alternative to M&A
2.12. The future of M&A in biopharma

3. Overview of M&A deal structure
3.1. Introduction
3.2. Pure versus multi-component acquisition deals
3.3. Pure M&A agreement structure
3.4. Acquisition as part of a wider alliance agreement
3.5. Merger agreements

4. Leading M&A deals
4.1. Introduction
4.2. Top M&A deals by value
4.3. Top merger deals
4.4. Bigpharma M&A deal activity

5. Bigpharma M&A deals
5.1. Introduction
5.2. How to use M&A deals
5.3. Bigpharma company M&A deal profiles

6. M&A contracts directory
6.1. Introduction
6.2. Company A-Z
6.3. By industry sector

Companies Mentioned:

  • Abbott Japan
  • Bristol-Myers Squibb
  • Cytokinetics
  • Dyax
  • Exelixis
  • GlaxoSmithKline
  • Hyperion Therapeutics
  • Ironwood Pharmaceuticals
  • Janssen Research & Development
  • KaloBios Pharmaceuticals
  • La Jolla Pharmaceutical
  • Millennium
  • Nycomed
  • Ortho Biotech
  • Procter & Gamble Pharmaceuticals
  • Seattle Genetics
  • Serono
  • Sigma-Tau
  • Solvay
  • Somaxon Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Transcept Pharmaceuticals
  • Ucyclyd Pharma
  • Victory Pharma
  • Warner Chilcott
  • Watson Pharmaceuticals
  • Wyeth
  • Xenoport
  • Zogenix
  • ZymoGenetics

For more information visit http://www.researchandmarkets.com/research/mqs7t3/merger_and

Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Spotlight Innovation, Inc. Announces Name Change and Closing of Merger
2. PharmAthene Announces Termination Of Merger Agreement With Theraclone Sciences
3. Steep Hill Laboratories and Halent Scientific Proudly Announce Historic Merger
4. 3SBio Inc. Announces Completion of Merger
5. 3SBio Inc. Enters Into Merger Agreement For "Going Private" Transaction
6. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
7. Epilepsy Foundation and Epilepsy Therapy Project Finalize Merger To Create Strong, Unified Organization To Support People with Epilepsy
8. Perrigo Company And Elan Corporation plc Receive Irish High Court Approval For Perrigos Proposed Acquisition Of Elan
9. Hart-Scott-Rodino Waiting Period Expires for Shires Acquisition of ViroPharma
10. Covington Advises Salix in $2.6 Billion Acquisition of Santarus
11. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):